Trials / Enrolling By Invitation
Enrolling By InvitationNCT06679946
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
- Status
- Enrolling By Invitation
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 700 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vutrisiran | Vutrisiran administered SC q3M |
Timeline
- Start date
- 2024-12-03
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
- First posted
- 2024-11-08
- Last updated
- 2026-02-20
Locations
87 sites across 17 countries: United States, Argentina, Austria, Belgium, Brazil, Czechia, Denmark, France, Italy, Netherlands, Norway, Portugal, South Korea, Spain, Sweden, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06679946. Inclusion in this directory is not an endorsement.